Pancreatic Cancer Research

ResearcherTohoku UniversityActive in the last 2 years

Nobumasa Mizuno

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9704-1885; OpenAlex author ID A5065581439. Sources: OpenAlex.

Their work

Papers
52 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
197
Papers, trials and grants by year

2011: 4 papers · 2012: 2 papers · 2013: 3 papers · 2014: 1 paper · 2015: 2 papers · 2016: 7 papers · 2017: 3 papers · 2018: 3 papers · 2019: 5 papers · 2020: 2 papers · 2021: 4 papers · 2022: 3 papers · 2023: 6 papers · 2024: 1 paper · 2025: 1 paper · 2026: 5 papers

Papers 50 of 52

  1. NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: results from an open-label, phase II study. Co-author DOI 10.1016/j.esmogo.2026.100365↗
  2. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… Co-author DOI 10.1093/jjco/hyag055↗
  3. Clinical Practice Guidelines for Pancreatic Cancer 2025 From the Japan Pancreas Society: A Synopsis. Co-author DOI 10.1097/mpa.0000000000002600↗
  4. High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-025-18912-3↗
  5. ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-026-19134-x↗
  6. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  7. Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer. Co-author DOI 10.1038/s41416-024-02834-0↗
  8. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  9. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Co-author DOI 10.1016/j.ejca.2022.12.014↗
  10. Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer. Co-author DOI 10.1038/s41416-023-02189-y↗
  11. Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgrou… Co-author DOI 10.1093/jjco/hyad044↗
  12. FOLFIRINOX in Pancreatic Cancer: Risk Factors for Febrile Neutropenia and Severe Neutropenia - Nationwide Study Analysis. Co-author DOI 10.21873/anticanres.16601↗
  13. Clinical utility of endoscopic ultrasound-guided tissue acquisition for comprehensive genomic profiling of pancreatic cancer. Co-author DOI 10.5946/ce.2022.086↗
  14. Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial … Co-author DOI 10.1093/jjco/hyab194↗
  15. Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer. Co-author DOI 10.1093/jjco/hyac110↗
  16. Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study. Co-author DOI 10.21873/anticanres.15547↗
  17. FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study. Co-author DOI 10.1007/s00280-020-04206-w↗
  18. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group… Co-author DOI 10.1093/jjco/hyaa198↗
  19. Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study. Co-author DOI 10.1097/mpa.0000000000001702↗
  20. Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer: An Integrated Analysis of Data From 2 Clinical Trials. Co-author DOI 10.1097/mpa.0000000000001879↗
  21. Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovaria… Co-author DOI 10.1007/s10147-020-01721-x↗
  22. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan. Co-author DOI 10.1016/j.pan.2020.07.006↗
  23. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE tri… Co-author DOI 10.1016/j.ejca.2018.10.004↗
  24. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japa… Co-author DOI 10.1016/j.pan.2019.01.001↗
  25. Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. Co-author DOI 10.1111/cas.13883↗
  26. Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer. Co-author DOI 10.18632/oncotarget.26633↗
  27. Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Panc… Co-author DOI 10.2169/internalmedicine.2362-18↗
  28. A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-018-3577-9↗
  29. Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic … Co-author DOI 10.1016/j.pan.2018.07.007↗
  30. Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. First author DOI 10.1097/mpa.0000000000001049↗
  31. A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gem… Co-author DOI 10.1007/s00280-017-3351-4↗
  32. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. Co-author DOI 10.1038/bjc.2016.436↗
  33. Familial pancreatic cancer: Concept, management and issues. Co-author DOI 10.3748/wjg.v23.i6.935↗
  34. Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-016-2972-3↗
  35. Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis … Co-author DOI 10.1016/j.ejca.2015.11.002↗
  36. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study. Co-author DOI 10.1016/j.pan.2016.04.007↗
  37. Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective cohort study. First author DOI 10.1016/j.pan.2016.05.007↗
  38. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdv603↗
  39. Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer: A Retrospective Cohort Study. First author DOI 10.1097/mpa.0000000000000446↗
  40. Clinical impact of preoperative endoscopic ultrasound-guided fine-needle aspiration for pancreatic ductal adenocarcinoma. Co-author DOI 10.4103/2303-9027.180472↗
  41. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Co-author DOI 10.1111/cas.12674↗
  42. [The clinical practice for the diagnosis of pancreatic cancer]. First author PMID 25856997↗
  43. EBM-based Clinical Guidelines for Pancreatic Cancer (2013) issued by the Japan Pancreas Society: a synopsis. Co-author DOI 10.1093/jjco/hyu127↗
  44. Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancrea… Co-author DOI 10.1007/s00535-012-0664-2↗
  45. Cytoplasmic expression of LGR5 in pancreatic adenocarcinoma. Co-author DOI 10.3389/fphys.2013.00269↗
  46. Cigarette smoking and pancreatic cancer risk: a revisit with an assessment of the nicotine dependence phenotype. Co-author DOI 10.7314/apjcp.2013.14.7.4409↗
  47. Seven-signal proteomic signature for detection of operable pancreatic ductal adenocarcinoma and their discrimination from autoimmune pancreatitis. Co-author DOI 10.1155/2012/510397↗
  48. Selected polymorphisms of base excision repair genes and pancreatic cancer risk in Japanese. Co-author DOI 10.2188/jea.je20120010↗
  49. Intravenous fluid therapy successfully prevents renal injury by gemcitabine in patients with pancreatic cancer. Last author DOI 10.1097/mpa.0b013e318214efce↗
  50. ABO blood group alleles and the risk of pancreatic cancer in a Japanese population. Co-author DOI 10.1111/j.1349-7006.2011.01907.x↗

Closest collaborators

The 25 strongest of 197 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Makoto Ueno · 19 shared papers, 2016–2026 · strength 1.88
  2. Masato Ozaka · 15 shared papers, 2018–2026 · strength 1.87
  3. Junji Furuse · 20 shared papers, 2014–2023 · strength 1.70
  4. Masafumi Ikeda · 18 shared papers, 2015–2024 · strength 1.67
  5. Naohiro Okano · 12 shared papers, 2018–2026 · strength 1.38
  6. Chigusa Morizane · 9 shared papers, 2017–2026 · strength 1.25
  7. Akiko Todaka · 10 shared papers, 2018–2023 · strength 1.01
  8. Takuji Okusaka · 13 shared papers, 2014–2023 · strength 1.01
  9. Satoshi Kobayashi · 10 shared papers, 2018–2023 · strength 1.00
  10. Tatsuya Ioka · 11 shared papers, 2016–2023 · strength 0.87
  11. Akira Fukutomi · 11 shared papers, 2015–2021 · strength 0.85
  12. Hiroshi Ishii · 9 shared papers, 2015–2023 · strength 0.80
  13. Kentaro Sudo · 7 shared papers, 2018–2024 · strength 0.78
  14. Hideki Ueno · 10 shared papers, 2015–2021 · strength 0.75
  15. Masayuki Furukawa · 8 shared papers, 2015–2024 · strength 0.72
  16. Keiko Kamei · 6 shared papers, 2018–2026 · strength 0.65
  17. Takeshi Terashima · 5 shared papers, 2017–2026 · strength 0.64
  18. Kenji Yamao · 15 shared papers, 2011–2016 · strength 0.61
  19. Toru Otsuru · 3 shared papers, 2023–2026 · strength 0.56
  20. Kazuo Hara · 9 shared papers, 2011–2023 · strength 0.55
  21. Yukihiro Yokoyama · 4 shared papers, 2012–2026 · strength 0.50
  22. Kumiko Umemoto · 4 shared papers, 2021–2024 · strength 0.49
  23. Katsuhiko Uesaka · 3 shared papers, 2014–2026 · strength 0.48
  24. Shoji Nakamori · 6 shared papers, 2016–2021 · strength 0.47
  25. Akinori Asagi · 4 shared papers, 2020–2024 · strength 0.47

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.